Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Dimerix Overview - Dimerix is developing DMX-200, a lead drug candidate in Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)[14] - FSGS is a rare kidney disease with no approved treatments, leading to irreversible kidney damage, dialysis, transplant, or death[14] - Dimerix has secured orphan drug designation for DMX-200, providing regulatory, marketing exclusivity, and pricing benefits in key territories[14] - Dimerix has licensing partners across key territories for DMX-200[14] Financial Achievements and Partnerships - Dimerix has received over AU$65 million in total payments to date[14,54] - Licensing deals are collectively valued up to approximately AU$1.4 billion in total upfront and potential milestone fees plus royalties[14,53] - A 3rd development and license agreement for DMX-200 in Japan is valued up to ¥10.5 billion (~AU$107 million) in upfront/milestones, plus royalties[17] - A 4th license agreement for DMX-200 in the United States is valued up to US$590 million (~AU$940 million) in upfront/milestones, plus royalties[17] Clinical Trial and Regulatory Progress - The FDA confirmed proteinuria as an acceptable endpoint for full marketing approval in the US[17] - The ACTION3 study has enrolled 225 patients, with 52 patients enrolled in the Open Label Extension Study as of August 5, 2025[33] - The Phase 3 trial aims to recruit a total of approximately 286 patients[33] - Dimerix held a positive Type C meeting with the FDA in March 2025 regarding proteinuria trial endpoints for full approval and potential accelerated approval for DMX-200[41] Market Opportunity - The estimated global incidence of FSGS is over 200,000 per year[61] - The estimated incidence of FSGS per year across all Dimerix licensed territories is approximately 50,071[61]

Market Drivers & Trends - Drone warfare is driving an urgent market need for counter-drone solutions[2,7] - The rapid rise of drones has changed the battlefield, with offense currently in the ascendant[13] - Effective counter-drone strategies require a layered response, with EOS products playing a complementary role[14] - High Energy Laser Weapons (HELW) meet many requirements for drone swarm defense, offering accuracy, speed, economy, and coverage[19] EOS's High Energy Laser Weapon (HELW) - EOS has signed a €71.4 million (~A$125 million) contract with a European customer for a 100-kW high energy laser system[4] - The 100kW system contract includes container module, laser modules, beam director and management system, system integration, documentation and support, power and cooling[36] - The system will be delivered over three years from EOS' facilities in Singapore[4] - EOS' main commercial focus is presently the 30-150kW power class of HELW[19] - Key technology is wholly owned by EOS, ITAR-free (no US content)[29] Competitive Landscape & Growth - The US market is dominated by large local primes, with >US$1 billion spend per annum on laser weapons[22] - EOS sees well-funded and growing customer interest in the European, Middle East & APAC markets for non-ITAR/non-US products[22] - EOS believes it has significant competitive advantages in laser weapons due to its expertise across multiple technically complex subsystems[22]

Market Opportunity and Unmet Needs - Achieve Life Sciences has a unique opportunity to address a market of up to 50 million Americans who use tobacco with Cytisinicline[6] - Nicotine dependence is a public health crisis costing billions of dollars[6] and there are ~29 million US smokers with few treatment options[12] - Approximately 60% of adult e-cigarette users want to quit[14], with ~17 million US adults reporting e-cigarette use[16] - An estimated $11 Billion Rx opportunity exists in the market[46] Cytisinicline's Potential and Clinical Data - Cytisinicline is presented as the first potential new nicotine dependence treatment option in nearly 20 years[6, 18] - ORCA-2 and ORCA-3 trials showed strong results in smoking cessation, demonstrating efficacy, tolerability, and craving reduction[22] - In the 12-week Cytisinicline Treatment, the quit rate is 32.6% compared to 7% in the placebo group[23] - In the 6-week Cytisinicline Treatment, the quit rate is 25.3% compared to 4.4% in the placebo group[23] - Phase 2 ORCA-V1 trial showed a 2.6x (p=0.035) increased likelihood of quitting vaping with cytisinicline[39] Commercialization Strategy - The company anticipates filing a Smoking cessation NDA with launch expected in 2H26[6] - A focused launch strategy will leverage innovative, data-driven solutions to drive adoption and future growth[7] - The company will focus on high-volume prescribers and engaged quitters[48] - The company will target the varenicline market share, which peaked at ~2.8M Rx (75% in U S market - $800M)[51]

For personal use only 2025 AUSTRALIAN RICE CONFERENCE Shaping the future Paul Serra SunRice Group CEO August 2025 2 0 2 5 A U S T R A L I A N R I C E C O N F E R E N C E Important notice & disclaimer This presentation has been prepared by Ricegrowers Limited (SunRice) and provides summary information only. SunRice has prepared this presentation in good faith believing the statements made in it to be true as at the date of the presentation. SunRice is not otherwise warranting the accuracy of the information ...

Equity Raising Overview - Silex is undertaking an equity raising of up to $130 million through a placement to eligible investors[11] - A share purchase plan (SPP) to eligible shareholders in Australia and New Zealand aims to raise up to $15 million[11] - The placement price is fixed at $3.90 per share, representing a 15.8% discount to the last close of $4.63 per share[42] and a 10.5% discount to the 5-day VWAP of $4.36 per share[42] - SPP shares will be issued at the lower of the placement price and a 2% discount to the 5-day VWAP up to the SPP closing date[42] Use of Proceeds - The proceeds from the offer, along with existing cash of approximately $69.6 million, will primarily support GLE's commercialization of the SILEX uranium enrichment technology in the US[41, 42] - Funds will also be used to pursue Silex's additional isotope production opportunities and strengthen the company's balance sheet[41, 42] - Silex expects to be fully funded through to the end of FY2028 following the placement[42] GLE Commercialization and Opportunities - GLE aims for commercial deployment of the SILEX uranium enrichment technology by 2030[40] - GLE's strategy includes potential production of UF6, LEU/LEU+, and HALEU at the Paducah Laser Enrichment Facility (PLEF)[41] - GLE has exclusive access to valuable uranium tails inventories from the US DOE, potentially producing up to 5 million lbs p a of natural grade uranium (as UF6) for up to 30 years[41, 74, 85]

For personal use only Bioshares Annual Conference Q&A presentation Hobart August 7, 2025 ® Xanamem is a registered trademark of Actinogen Medical Limited Disclaimer For personal use only Bioshares Q&A August 7, 2025 2 • This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make a ...

Capital Raising and Financial Position - Liontown is undertaking a capital raising of approximately A$266 million to strengthen its balance sheet and provide a liquidity buffer[38, 42] - The pro forma cash balance after the capital raising is expected to be approximately A$422 million before transaction costs[42, 99] - The National Reconstruction Fund Corporation (NRFC) is investing A$50 million in Liontown as part of the capital raising at A$0.73 per share[42, 105] Operational Performance and Future Plans - In FY25, Liontown produced over 320,000 wmt of concentrate at 5.2% Li2O with 8% moisture, equivalent to over 294,000 dmt[38, 53] - Underground production stoping has commenced on schedule[38] - FY26 is expected to be a transition year for Kathleen Valley as underground production ramps up, with 100% underground production planned by Q3 FY26[42, 60] - A lithia recovery target of 70% by Q3 FY26 remains unchanged[42, 60] Financial Metrics and Guidance - FY25 revenue was A$301 million with an average realised price of A$1,061 per dmt (CIF) for ~SC5[53] - H2 FY25 unit operating cost was A$802 per dmt sold (FOB), and AISC was A$1,081 per dmt sold (FOB)[53] - FY26 concentrate production is guided at 365,000 - 450,000 dmt, with All in Sustaining Costs of A$1,060 - A$1,295 per dmt sold and Unit Operating Costs of A$855 - A$1,045 per dmt sold[61]

Financial Performance - Q2 2025 net sales reached $1.3 billion, aligning closely with the midpoint of the company's guidance range[12] - Adjusted EBITDA for Q2 2025 was $174 million, surpassing the company's guidance[12] - The company repaid $55 million in debt, including $50 million of 2025 Notes[12] - The company's gross profit margin increased by 10 bps year-over-year to 78%[31] - Adjusted diluted EPS was $0.59, which includes an $0.11 year-over-year foreign exchange headwind[31] Regional Performance - New distributor growth occurred in 4 out of 5 regions year-over-year, with Latin America leading at a 16% increase[12] - Worldwide net sales decreased by 1.7% year-over-year, but remained flat on a constant currency basis[34] - Latin America experienced a 9% increase in local currency net sales[34] Product Launches and Initiatives - The company launched the Herbalife Flex45 Challenge globally[12] - The company expanded the Diamond Development Mastermind Program to South and Central America[12] - The company launched MultiBurn, a multifunctional weight-loss supplement[12] - The company unveiled the beta version of the Pro2col digital platform[12] Future Outlook - The company projects net sales to increase between 0.5% and 4.5% year-over-year for Q3 2025[42] - The company anticipates adjusted EBITDA between $150 million and $160 million for Q3 2025[42] - The company expects full-year 2025 net sales to range from a decrease of 1% to an increase of 3% year-over-year[42]

Q2 2025 Financial Performance - Adjusted EPS reached $5.13, a 13% year-over-year increase, or 17% on a constant macro basis[10] - Revenues totaled $1.102 billion, up 13% year-over-year[10] - Adjusted EBITDA was $621 million, a 12% year-over-year increase[10] - The company reported organic revenue growth of 11%[10] - Revenue retention improved to 92.3%[10] Segment Performance - Corporate Payments revenue grew by 18%[10] - Vehicle Payments organic revenue growth was 9%[16] - Lodging Payments experienced a decline of 2%[16] - Other segments, including Gift and Payroll Cards, grew by 18%[16] Liquidity and Capital Allocation - Liquidity as of June 30, 2025, was approximately $3.5 billion[23] - Adjusted EBITDA was reported as $621 million[26] - Free cash flow generated was $366 million[26] - The company's leverage ratio was 2.53x[23] 2025 Guidance - The company projects second-half adjusted EPS to accelerate to $11.40, an 18% increase over the first half of 2025[32] - Organic revenue growth in the second half is expected to be 10%[32]